Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hang Quach

Showing results (21-30 of 119) with videos related to

Pageof 12
Sort By:
Frontiers in Immunology|October 5, 2020
Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T CellsRachel Elizabeth Cooke, Kylie Margaret Quinn, Hang Quach, et al.
Leukemia & Lymphoma|February 6, 2009
Predicting durable remissions following thalidomide therapy for relapsed myelomaHang Quach, Linda Mileshkin, John F Seymour, et al.
American Journal of Hematology|October 7, 2009
Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemiaCrisoula Batzios, Lachlan A Hayes, Simon Z He, et al.
Expert Review of Proteomics|November 7, 2022
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory diseasePaul G Richardson, María-Victoria Mateos, Annette J Vangsted, et al.
Cancer Chemotherapy and Pharmacology|April 21, 2017
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I studyHang Quach, Darrell White, Andrew Spencer, et al.
Journal of Translational Medicine|September 8, 2016
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myelomaRachel E Cooke, Nicholas A Gherardin, Simon J Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 14, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR TrialKatja Weisel, Maria-Victoria Mateos, Ola Landgren, et al.
British Journal of Haematology|June 26, 2023
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)Andrew Spencer, Anna Kalff, Jake Shortt, et al.
Blood Advances|May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Clinical & Translational Immunology|January 13, 2021
Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myelomaMarcel Doerflinger, Alexandra L Garnham, Saskia Freytag, et al.
Pageof 12

Showing results (21-30 of 119) with videos related to

Sort By:
Pageof 12
Frontiers in Immunology|October 5, 2020
Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T CellsRachel Elizabeth Cooke, Kylie Margaret Quinn, Hang Quach, et al.
Leukemia & Lymphoma|February 6, 2009
Predicting durable remissions following thalidomide therapy for relapsed myelomaHang Quach, Linda Mileshkin, John F Seymour, et al.
American Journal of Hematology|October 7, 2009
Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemiaCrisoula Batzios, Lachlan A Hayes, Simon Z He, et al.
Expert Review of Proteomics|November 7, 2022
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory diseasePaul G Richardson, María-Victoria Mateos, Annette J Vangsted, et al.
Cancer Chemotherapy and Pharmacology|April 21, 2017
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I studyHang Quach, Darrell White, Andrew Spencer, et al.
Journal of Translational Medicine|September 8, 2016
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myelomaRachel E Cooke, Nicholas A Gherardin, Simon J Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 14, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR TrialKatja Weisel, Maria-Victoria Mateos, Ola Landgren, et al.
British Journal of Haematology|June 26, 2023
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)Andrew Spencer, Anna Kalff, Jake Shortt, et al.
Blood Advances|May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Clinical & Translational Immunology|January 13, 2021
Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myelomaMarcel Doerflinger, Alexandra L Garnham, Saskia Freytag, et al.
Pageof 12